60 Degrees Pharmaceuticals, Inc.

60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the prevention and treatment of infectious diseases. Founded in 2010, the company's mission is to address unmet medical needs by providing new best-in-class medicines, particularly for tropical and vector-borne diseases. Its headquarters are located in Washington, D.C., USA.

The company's lead product is ARAKODA (tafenoquine), an FDA-approved medication for malaria prevention since 2018, which is also available in Australia as KODATEF. Its pipeline includes tafenoquine in clinical development for babesiosis, fungal pneumonias (such as Pneumocystis and Candida species), and candidiasis. Additionally, 60 Degrees Pharmaceuticals is developing Celgosivir for Zika, respiratory viruses, and dengue.

Led by CEO, President, and Director Geoffrey Dow, 60 Degrees Pharmaceuticals has recently expanded its sales and marketing efforts for ARAKODA, including a new partnership with GoodRx and enhanced digital campaigns in 2026. ARAKODA is now also accessible to U.S. travelers via the Runway Health telehealth website. The company reported increased net product revenues and an improved net loss in its FY2025 results. Notable clinical progress includes all patients being cured of babesiosis after tafenoquine treatment in an expanded use clinical trial. In January 2026, the company effected a one-for-four reverse stock split to maintain compliance with Nasdaq's minimum bid price requirement.